Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. | Available online http content 11 3 234 Review Molecular therapies for systemic lupus erythematosus clinical trials and future prospects Fanny Monneaux and Sylviane Muller CNRS Immunologie et Chimie Thérapeutiques Institut de Biologie Moléculaire et Cellulaire 15 rue René Descartes 67000 Strasbourg France Corresponding author Sylviane Muller Published 30 June 2009 This article is online at http content 11 3 234 2009 BioMed Central Ltd Arthritis Research Therapy 2009 11 234 doi ar2711 Abstract The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases. Toxic effects and sometimes unexpectedly dramatic complications of current therapies have been progressively reported. Identifying novel molecular targets therefore remains an important issue in the treatment of lupus. The aim of this review article is to highlight emerging pharmacological options and new therapeutic avenues for lupus with a particular focus on non-antibody molecular strategies. Introduction Systemic lupus erythematosus SLE is a chronic autoimmune disease characterized by unpredictable exacerbations and remissions with diverse clinical manifestations. The latter may range from nonspecific symptoms such as fatigue and arthralgia to life-threatening renal and neurological manifestations. Women of childbearing age and certain minorities are disproportionately affected. A prevalence of several hundred thousand patients with lupus has been estimated in the United States - it may in fact approach 1 million to 2 million individuals according to the Lupus Foundation of America - and almost the same figures are given in Europe. .
